May 19th, 2017|
Eliquis® (apixaban) is the latest of the new-age blood thinners to have lawsuits against its manufacturers (Bristol-Myers Squibb and Pfizer) consolidated into a multi-district litigation (MDL). On February 7, 2017, the Judicial Panel on Multidistrict Litigation agreed to centralize the Eliquis lawsuits before Judge Denise Cote in the Southern District of New York. This consolidation will allow claims filed against the manufacturers of Eliquis to move more quickly and efficiently.
INJURIES RESULTING FROM ELIQUIS® USE
Eliquis® was approved by the FDA in 2012. Much like the blood thinners Pradaxa and Xarelto, Eliquis® is prescribed to treat and prevent atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). However, unlike older anticoagulants such as Coumadin/Warfarin, these new-age blood thinners, including Eliquis®, have no antidote to reverse their effects for a patient experiencing a severe bleeding event or needing emergency surgery. As a result, patients prescribed Eliquis® are at an increased risk for severe adverse bleeding events including:
- Irreversible Fatal Bleeding Events
- Gastrointestinal (GI) Bleeds
- Rectal Bleeding
- Brain Bleeds
- Intracranial Hemorrhages
- Hemorrhagic Strokes
LAWSUITS BEING FILED AGAINST ELIQUIS® MANUFACTURERS
Now, victims of these severe adverse bleeding events are fighting back. Claims against Eliquis® manufactures include failure to warn patients and prescribing physicians of the increased risks of bleeding as well as allegations that Eliquis® manufacturers fraudulently promoted the drug as at least as safe and effective as older anticoagulants while concealing unfavorable study results from the FDA, public, and health community.
WE’RE HERE FOR YOU 24/7
At Cory Watson Attorneys, we have made it our mission to fight for the rights of injury victims and their families for more than 30 years, and have recovered over $2.7 Billion for our clients.
Call (877) 562-0000 or fill out our online form to arrange for your FREE and CONFIDENTIAL case evaluation.